239 related articles for article (PubMed ID: 15023866)
1. Neurokinin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain.
Sanger GJ
Br J Pharmacol; 2004 Apr; 141(8):1303-12. PubMed ID: 15023866
[TBL] [Abstract][Full Text] [Related]
2. Defensive and pathological functions of the gastrointestinal NK3 receptor.
Sanger GJ; Tuladhar BR; Bueno L; Furness JB
Vascul Pharmacol; 2006 Oct; 45(4):215-20. PubMed ID: 16901762
[TBL] [Abstract][Full Text] [Related]
3. Tachykinins in the gut. Part I. Expression, release and motor function.
Holzer P; Holzer-Petsche U
Pharmacol Ther; 1997; 73(3):173-217. PubMed ID: 9175155
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of Nk1 and NK3 neurokinin receptors in neurons of the nucleus tractus solitarius and the dorsal vagal motor nucleus of the rat and mouse.
Le Brun I; Dufour A; Crest M; Szabó G; Erdelyi F; Baude A
Neuroscience; 2008 Mar; 152(1):56-64. PubMed ID: 18222044
[TBL] [Abstract][Full Text] [Related]
5. Tachykinins and tachykinin receptors in the gut, with special reference to NK2 receptors in human.
Lecci A; Capriati A; Altamura M; Maggi CA
Auton Neurosci; 2006 Jun; 126-127():232-49. PubMed ID: 16616700
[TBL] [Abstract][Full Text] [Related]
6. Characterization of receptors mediating contraction induced by tachykinins in the guinea-pig isolated common bile duct.
Patacchini R; Barthó L; Maggi CA
Br J Pharmacol; 1997 Dec; 122(8):1633-8. PubMed ID: 9422808
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia.
Dawson LA; Cato KJ; Scott C; Watson JM; Wood MD; Foxton R; de la Flor R; Jones GA; Kew JN; Cluderay JE; Southam E; Murkitt GS; Gartlon J; Pemberton DJ; Jones DN; Davies CH; Hagan J
Neuropsychopharmacology; 2008 Jun; 33(7):1642-52. PubMed ID: 17728699
[TBL] [Abstract][Full Text] [Related]
8. Distinct regional distributions of NK1 and NK3 neurokinin receptor immunoreactivity in rat brainstem gustatory centers.
Harrison TA; Hoover DB; King MS
Brain Res Bull; 2004 Mar; 63(1):7-17. PubMed ID: 15121234
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of potential dual NK(1)/NK(3) receptor antagonists.
Hanessian S; Babonneau V; Boyer N; Mannoury la Cour C; Millan MJ; De Nanteuil G
Bioorg Med Chem Lett; 2014 Jan; 24(2):510-4. PubMed ID: 24374277
[TBL] [Abstract][Full Text] [Related]
10. Targeting tachykinin receptors for the treatment of functional gastrointestinal disorders with a focus on irritable bowel syndrome.
Corsetti M; Akyuz F; Tack J
Neurogastroenterol Motil; 2015 Oct; 27(10):1354-70. PubMed ID: 26088804
[TBL] [Abstract][Full Text] [Related]
11. Discovery of potent, balanced and orally active dual NK1/NK3 receptor ligands.
Peters JU; Hoffmann T; Schnider P; Stadler H; Koblet A; Alker A; Poli SM; Ballard TM; Spooren W; Steward L; Sleight AJ
Bioorg Med Chem Lett; 2010 Jun; 20(11):3405-8. PubMed ID: 20430616
[TBL] [Abstract][Full Text] [Related]
12. Tachykinin receptors and receptor subtypes.
Patacchini R; Maggi CA
Arch Int Pharmacodyn Ther; 1995; 329(1):161-84. PubMed ID: 7639617
[TBL] [Abstract][Full Text] [Related]
13. Mediation of irregular spiking activity by multiple neurokinin-receptors in the small intestine of the rat.
Lördal M; Bränström R; Hellström PM
Br J Pharmacol; 1998 Jan; 123(1):63-70. PubMed ID: 9484855
[TBL] [Abstract][Full Text] [Related]
14. Tachykinin NK1 and NK3 receptors in the prefrontal cortex of the human brain.
Tooney PA; Au GG; Chahl LA
Clin Exp Pharmacol Physiol; 2000 Nov; 27(11):947-9. PubMed ID: 11071316
[TBL] [Abstract][Full Text] [Related]
15. Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility.
Gershon MD
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():3-14. PubMed ID: 15521849
[TBL] [Abstract][Full Text] [Related]
16. Functional characterization of the human neurokinin receptors NK1, NK2, and NK3 based on a cellular assay system.
Stratowa C; Machat H; Burger E; Himmler A; Schafer R; Spevak W; Weyer U; Wiche-Castanon M; Czernilofsky AP
J Recept Signal Transduct Res; 1995; 15(1-4):617-30. PubMed ID: 8903968
[TBL] [Abstract][Full Text] [Related]
17. Neurokinin receptor modulation of respiratory activity in the rabbit.
Bongianni F; Mutolo D; Cinelli E; Pantaleo T
Eur J Neurosci; 2008 Jun; 27(12):3233-43. PubMed ID: 18554294
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel NK1/NK3 dual antagonists for the potential treatment of schizophrenia.
Catalani MP; Alvaro G; Bernasconi G; Bettini E; Bromidge SM; Heer J; Tedesco G; Tommasi S
Bioorg Med Chem Lett; 2011 Nov; 21(22):6899-904. PubMed ID: 21974957
[TBL] [Abstract][Full Text] [Related]
19. Activity of cyclic pseudopeptide antagonists at peripheral tachykinin receptors.
Patacchini R; Quartara L; Astolfi M; Goso C; Giachetti A; Maggi CA
J Pharmacol Exp Ther; 1995 Mar; 272(3):1082-7. PubMed ID: 7891319
[TBL] [Abstract][Full Text] [Related]
20. The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity.
Tian Y; Wu LH; Oxender DL; Chung FZ
J Biol Chem; 1996 Aug; 271(34):20250-7. PubMed ID: 8702757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
